All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

PHARMACOMPASS

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

Product Type

Companies

Elixiron Immunotherapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

TAIWAN Taiwan

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Elixiron Immunotherapeutics Awarded Alzheimer's Association Grant to Target Microglia in Alzheimer's Disease

Lead Product(s): EI1071

Therapeutic Area: Neurology Product Name: EI1071

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Alzheimer's Association

Deal Size: $1.0 million Upfront Cash: Undisclosed

Deal Type: Funding August 26, 2020

Details:

Grant Program will support a U.S. FDA-approved first-in-human phase 1 clinical trial of its lead drug candidate, EI1071, an orally available, highly potent Colony-Stimulating Factor 1 Receptor (CSF1R) inhibitor.